

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF

the specification of which (I authorize Choate, Hall & Stewart to check one of the following, three choices, and fill in the blanks, if applicable):

 X is attached hereto

 was filed on as Application Serial No. and amended on (if applicable).

 was filed as PCT international application No. ,
on and was amended under PCT Article 19
on (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledged the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

Priority Claimed

<u> </u> (Number)	<u> </u> (Country)	<u> </u> (Day/Month/Year/Filed)	<u> </u> Yes	<u> </u> No
<u> </u> (Number)	<u> </u> (Country)	<u> </u> (Day/Month/Year/Filed)	<u> </u> Yes	<u> </u> No
<u> </u> (Number)	<u> </u> (Country)	<u> </u> (Day/Month/Year/Filed)	<u> </u> Yes	<u> </u> No

SECRET

PCT Applications designating the United States:

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national filing date of this application.

<u>60/150,088</u>	<u>August 20, 2000</u>	<u>pending</u>
(Application Serial No.)	(filing date)	(status)

- 2 -

Full name of first inventor Samuel J. Danishefsky

Inventor's signature _____ Date: _____

Residence 22 Brayton Street, Englewood, New Jersey 07631

Citizenship U.S.

Post Office Address same

Full name of second inventor Jennifer R. Allen

Inventor's signature _____ Date: _____

Residence 5886 North Delaware Street, Indianapolis, Indiana 46220

Citizenship U.S.

Post Office Address same

Full name of third inventor Govindaswami Ragupathi

Inventor's signature _____ Date: _____

Residence 504 East 81st Street, New York, New York 10028

Citizenship India

Post Office Address same

Full name of fourth inventor Philip O. Livingston

Inventor's signature _____ Date: _____

Residence 156 East 79th Street, New York, New York 10021

Citizenship U.S.

Post Office Address same

3158767

ATTORNEY DOCKET NO.: 2003080-0054

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Danishefsky *et al.* Examiner:
Serial No.: not assigned yet Art Unit:
Filed: August 18, 2000
For: *Novel Glycoconjugates, Glycoamino Acids, Intermediates Thereto, and Uses Thereof*

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

APPOINTMENT OF ATTORNEY

The undersigned hereby appoints Karoline K.M. Shair, Registration No. 44,332; Brenda Herschbach Jarrell, Registration No. 39,223; Sam Pasternack, Registration No. 29,576; Kevin M. Tormey, Registration No. 41,351; Elizabeth Nugent, Registration No. 43,839; Valarie B. Rosen, Registration No. 45,698; Stanley C. Mah, Registration No. 46,189; Anne-Marie Dinius, Registration No. 45,592; Hunter C. Baker, Registration No. P-46,533 and Monica Gerber, Registration No. P-46,724; as its attorneys and agents for prosecution of matters relating to the above-identified patent application and to conduct all business in the United States Patent and Trademark Office.

All correspondence should be sent to Karoline K.M. Shair, Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, Massachusetts 02109.

Respectfully submitted,

Name: _____
Title: _____
On behalf of Sloan-Kettering Institute for Cancer Research

Dated:

3158766

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Danishefsky *et al.* Examiner:
Serial No.: not assigned yet Art Unit:
Filed: August 18, 2000
For: *Novel Glycoconjugates, Glycoamino Acids, Intermediates Thereto, and Uses Thereof*

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Sir:

ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION
(37 CFR 3.73(b))

The assignee of the entire right, title and interest, Sloan-Kettering Institute for Cancer Research, hereby seeks to take action in the Patent and Trademark Office in the above-referenced matter.

Ownership by the assignee is established as follows:

documents already recorded in the PTO on _____

Reel _____ Frame _____; and

documents already recorded in the PTO on _____

Reel _____ Frame _____

_____ documents separately submitted for recordal to the PTO (a copy of these documents are attached).

COLORED PEOPLE

Examiner:
Art Unit:

37 CFR 1.9(f) and 1.27(d)

TYPE OF ORGANIZATION:

- () Would qualify as tax exempt under the Internal Revenue Service Code (26 USC § 501(a) and § 501(c) (3) if the organization were located in the United States of America

I hereby declare that the above-identified non-profit organization qualifies as a non-profit organization as defined in 37 CFR 1.9(e), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code.

I hereby declare that rights under contract or law have been conveyed to and remain with the above-identified non-profit organization with regard to the invention titled:

TITLE: Novel Glycoconjugates, Glycoamino Acids, Intermediates Thereto, and Uses Thereof

by:

INVENTORS: Samuel J. Danishefsky, Jennifer R. Allen, Govindaswami Ragupathi and Philip O. Livingston

described in:

☒ (X) the specification filed herewith

☐ () U.S. Patent Application Serial Number _____
filed _____

☐ () U.S. Patent Number _____
issued _____

If the rights of the above-identified non-profit organization are not exclusive, each individual, concern, or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor(s), who could not qualify as a small business concern under 37 CFR § 1.9(d) or a non-profit organization under 37 CFR § 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention, averring to their status as small entities. (37 CFR § 1.27).

FULL NAME: _____

ADDRESS: _____

☐ () INDIVIDUAL ☐ () SMALL BUSINESS CONCERN ☐ () NON-PROFIT ORGANIZATION

FULL NAME: _____

ADDRESS: _____

☐ () INDIVIDUAL ☐ () SMALL BUSINESS CONCERN ☐ () NON-PROFIT ORGANIZATION

FULL NAME: _____

ADDRESS: _____

☐ () INDIVIDUAL ☐ () SMALL BUSINESS CONCERN ☐ () NON-PROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR § 1.28(b))

003120 "244" 244

[illegible]

SIGNATURE: _____ DATE: _____

3158757